Multiple myeloma and acute leukemia associated with alkylating agents

Area of Science:

• Hematology
• Oncology
• Medical Research

Background:

• Multiple myeloma is a cancer of plasma cells.
• Melphalan is an alkylating agent used in multiple myeloma treatment.
• Secondary malignancies can arise as a complication of cancer therapy.

Purpose of the Study:

• To report on the occurrence of acute myelomonocytic leukemia in patients with multiple myeloma.
• To investigate the potential link between melphalan treatment and the development of secondary leukemia.
• To differentiate between acute myelomonocytic leukemia and plasma cell leukemia in this context.

Main Methods:

• Case series of five patients with multiple myeloma.
• Analysis of treatment history, focusing on melphalan duration (28-54 months).
• Postmortem examination to assess leukemic infiltration and myeloma evidence.

Main Results:

• Five patients developed rapidly fatal acute myelomonocytic leukemia.
• Multiple myeloma responded to melphalan therapy prior to leukemia development.
• Postmortem findings showed significant leukemic infiltration with minimal myeloma evidence.

Conclusions:

• The cases suggest a higher incidence of acute leukemia in multiple myeloma patients treated with alkylating agents.
• Acute myelomonocytic leukemia is the likely diagnosis, not plasma cell leukemia.
• Alkylating agents like melphalan may contribute to the development of secondary acute leukemia.